132 related articles for article (PubMed ID: 18694370)
21. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
Lam MG; de Klerk JM; Zonnenberg BA
J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
23. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
[TBL] [Abstract][Full Text] [Related]
25. An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results.
Kendler D; Donnemiller E; Oberladstätter M; Erler H; Gabriel M; Riccabona G
Nucl Med Commun; 2004 Apr; 25(4):367-73. PubMed ID: 15097811
[TBL] [Abstract][Full Text] [Related]
26. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
27. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
28. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
29. The importance of BMI in dosimetry of
Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
[TBL] [Abstract][Full Text] [Related]
30. Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget's disease and rheumatoid arthritis.
Alberts AS; Brighton SW; Kempff P; Louw WK; Beek AV; Kritzinger V; Westerink HP; van Rensburg AJ
J Nucl Med; 1995 Aug; 36(8):1417-20. PubMed ID: 7543145
[TBL] [Abstract][Full Text] [Related]
31. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
[TBL] [Abstract][Full Text] [Related]
32. Samarium-153Sm-EDTMP as an equivalent variant to pharmaceutical analgesic treatment.
Tsoucalas G; Sarafianou E; Galanos A; Parpa E; Baziotis N; Sgantzos M; Gennimata V; Lymperi M; Patiraki E; Kouloulias V; Mystakidou K
J BUON; 2014; 19(4):1083-91. PubMed ID: 25536620
[TBL] [Abstract][Full Text] [Related]
33. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.
Paravati AJ; Russo AL; Aitken C
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):506-10. PubMed ID: 20888141
[TBL] [Abstract][Full Text] [Related]
34. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
Shi B; Fu Z; Lei XH
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
[TBL] [Abstract][Full Text] [Related]
35. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
36. Europium radionuclides in samarium-153-Ethylene Diamine Tetramethylene phosphonic acid (
Mishra SG; Sawant DK; Chindarkar AS; Thamke AN; Sanjeev Kumar B; Dey AC; Kulkani MS
Appl Radiat Isot; 2022 Oct; 188():110386. PubMed ID: 35939938
[No Abstract] [Full Text] [Related]
37. [Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].
Feng JY; Wu CQ; Zhang P; Wang SJ; Zheng XH
Zhonghua Nan Ke Xue; 2012 Nov; 18(11):982-5. PubMed ID: 23214246
[TBL] [Abstract][Full Text] [Related]
38. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
39. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I
Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
[TBL] [Abstract][Full Text] [Related]
40. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
